ProCE Banner Activity

HERIZON-BTC-01: Zanidatamab, a HER2-Targeted Bispecific Antibody, in Previously Treated HER2‑Amplified Biliary Tract Cancer

Conference Coverage
Slideset

Rapid and durable responses observed with zanidatamab in previously treated patients with HER2-amplified, locally advanced unresectable or metastatic BTC in the HERIZON-BTC-01 study.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen